Newtyn Management, LLC - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 126 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2021. The put-call ratio across all filers is 0.56 and the average weighting 0.1%.

Quarter-by-quarter ownership
Newtyn Management, LLC ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$15,892,663
-6.4%
1,841,560
+12.3%
3.92%
-2.2%
Q2 2023$16,978,720
+2.2%
1,640,456
+7.1%
4.01%
+22.9%
Q1 2023$16,611,513
+2.1%
1,531,015
+5.6%
3.26%
-2.8%
Q4 2022$16,269,000
-35.7%
1,450,000
-41.9%
3.36%
-39.6%
Q3 2022$25,308,000
+37.1%
2,495,860
+22.5%
5.56%
+58.8%
Q2 2022$18,463,000
+40.5%
2,037,825
+48.2%
3.50%
+11.1%
Q1 2022$13,145,000
+19.0%
1,375,000
+37.5%
3.15%
+7.3%
Q4 2021$11,050,000
+1424.1%
1,000,000
+920.9%
2.93%
+1419.7%
Q3 2021$725,000
-83.8%
97,955
-43.5%
0.19%
-53.4%
Q4 2019$4,487,000
+261.6%
173,300
+172.1%
0.41%
+253.8%
Q3 2019$1,241,00063,6810.12%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2021
NameSharesValueWeighting ↓
Woodford Investment Management Ltd 10,898,879$264,297,00023.51%
Foundation Asset Management, LP 399,537$9,689,0003.59%
Cormorant Asset Management, LP 1,300,000$31,525,0002.35%
Baupost Group 9,309,168$225,747,0002.18%
Old West Investment Management, LLC 109,320$2,651,0001.53%
SENZAR ASSET MANAGEMENT, LLC 187,856$4,555,0001.44%
Chescapmanager LLC 350,631$8,503,0001.27%
Virtus ETF Advisers LLC 32,989$800,0000.69%
Rock Springs Capital Management LP 652,600$15,826,0000.68%
NJ State Employees Deferred Compensation Plan 34,142$828,0000.15%
View complete list of THERAVANCE BIOPHARMA INC shareholders